|
Congenital kyphoscoliosis
|
0.200 |
Biomarker
|
disease |
RGD |
Abnormalities of vertebral formation and Hox expression in congenital kyphoscoliotic rats.
|
18327665 |
2008 |
|
Kyphoscoliosis deformity of spine
|
0.200 |
Biomarker
|
disease |
RGD |
Abnormalities of vertebral formation and Hox expression in congenital kyphoscoliotic rats.
|
18327665 |
2008 |
|
Acquired Kyphoscoliosis
|
0.200 |
Biomarker
|
disease |
RGD |
Abnormalities of vertebral formation and Hox expression in congenital kyphoscoliotic rats.
|
18327665 |
2008 |
|
Breast Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Blocking HOXC10 function, therefore, presents a promising new strategy to overcome chemotherapy resistance in breast cancer.
|
27302171 |
2016 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
We validated significant overexpression of transcripts for HOXC10 (P=0.001), TPD52L1 (P=0.007), ZFP36L1 (P=0.011), PLINP1 (P=0.013), DCTN3 (P=0.025), DEK (P=0.031), and CSNK1D (P=0.04) in lymph node (+) breast carcinomas.
|
17855657 |
2007 |
|
Breast Carcinoma
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer.
|
24670685 |
2014 |
|
Breast Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
We found that HOXC10 is overexpressed in breast cancer and transcriptionally regulated by estrogen (17β-estradiol, E(2)).
|
22143955 |
2012 |
|
Malignant neoplasm of breast
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer.
|
24670685 |
2014 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Blocking HOXC10 function, therefore, presents a promising new strategy to overcome chemotherapy resistance in breast cancer.
|
27302171 |
2016 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We found that HOXC10 is overexpressed in breast cancer and transcriptionally regulated by estrogen (17β-estradiol, E(2)).
|
22143955 |
2012 |
|
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
HOXC10 should be explored as a clinical marker of GC prognosis.
|
29753747 |
2018 |
|
Malignant neoplasm of stomach
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
HOXC10 expression was determined in gastric cancer tissues acquired from 300 patients with gastric cancer.
|
30673899 |
2019 |
|
Malignant neoplasm of stomach
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
HOXC10 overexpression promotes cell proliferation and migration in gastric cancer.
|
31115563 |
2019 |
|
Stomach Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
HOXC10 should be explored as a clinical marker of GC prognosis.
|
29753747 |
2018 |
|
Stomach Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
HOXC10 expression was determined in gastric cancer tissues acquired from 300 patients with gastric cancer.
|
30673899 |
2019 |
|
Stomach Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
HOXC10 overexpression promotes cell proliferation and migration in gastric cancer.
|
31115563 |
2019 |
|
Squamous cell carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Upregulation of HOXC10 indicated a poor overall survival of OSCC patients according to the Kaplan-Meier survival curves.
|
31528218 |
2019 |
|
Squamous cell carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Gene expression analysis of preinvasive and invasive cervical squamous cell carcinomas identifies HOXC10 as a key mediator of invasion.
|
17974957 |
2007 |
|
Glioblastoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In three independent datasets (REMBRANDT glioma, The Cancer Genome Atlas glioblastoma multiforme and GSE4412), HOXC10 upregulation was associated with short overall survival.
|
29676849 |
2018 |
|
Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Cell proliferation, migration and invasion were assessed using the Cell Counting Kit-8 (CCK-8) and colony formation assay, wound healing, Transwell assay, respectively in GBM U87 cell after HOXC10 knockdown.
|
29768063 |
2019 |
|
Glioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> This study suggests that HOXC10 induces glioma angiogenesis by transcriptionally upregulating <i>VEGFA</i> expression, and may represent a potential target for antiangiogenic therapy in gliomas.
|
30429891 |
2018 |
|
Glioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In summary, our results suggest that HOXC10 upregulation in glioma promotes an aggressive phenotype and induces immunosuppressive gene expression, supporting further investigation of the potential of HOXC10 as a therapeutic target in glioma.
|
29676849 |
2018 |
|
Osteosarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These results indicated that HOXC10 might be a diagnostic marker for osteosarcoma and could be a potential molecular target for the therapy of osteosarcoma.
|
28474998 |
2017 |
|
Osteosarcoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
HOXC10 might function as an oncogene in OS by regulating the expression and activity of caspase 3.
|
29403292 |
2018 |
|
Osteosarcoma of bone
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
HOXC10 might function as an oncogene in OS by regulating the expression and activity of caspase 3.
|
29403292 |
2018 |